Drug latentiation in cancer chemotherapy

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Oncology

Background:

• Latent antitumour agents require in vivo activation to become cytotoxic.
• Activation can occur in normal tissues or target tumours.
• Current agents face challenges in achieving selective tumour activation.

Purpose of the Study:

• To discuss latent antitumour agents and their activation mechanisms.
• To analyze the reasons for poor therapeutic activity of tumour-selective agents.
• To explore novel approaches for designing enzyme-activated anticancer drugs.

Main Methods:

• Review and discussion of existing latent antitumour agents.
• Analysis of drug action and selectivity mechanisms.
• Examination of enzyme distribution in normal versus neoplastic tissues.

Main Results:

• Selective activation in tumours is often hindered by unfavourable enzyme distribution.
• The design of effective enzyme-activated agents requires careful consideration of enzyme localization.
• Artefacts in tumour enzyme assays can impact drug development.

Conclusions:

• Optimizing latent antitumour agent design necessitates understanding enzyme kinetics and distribution.
• Novel strategies are needed to overcome challenges in selective tumour activation.
• Further research into enzyme-activated prodrugs holds therapeutic promise.